Institutional investors may overlook BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) recent US$62m market cap drop as long-term gains remain positive

Simply Wall St.10-11

Key Insights Institutions' substantial holdings in BioCryst Pharmaceuticals implies that they have significant influence over the company's share price A total of 12 investors have a majority stake...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2474018585?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2024-10-11 21:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2474018585","market":"us","top_or_hot":-1,"title":"Institutional investors may overlook BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) recent US$62m market cap drop as long-term gains remain positive","media":"Simply Wall St.","content":"<div>\n<p>Key Insights  Institutions' substantial holdings in BioCryst Pharmaceuticals implies that they have significant influence over the company's share price   A total of 12 investors have a majority stake...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/institutional-investors-may-overlook-biocryst-pharmaceutical-1\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Institutional investors may overlook BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) recent US$62m market cap drop as long-term gains remain positive</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInstitutional investors may overlook BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) recent US$62m market cap drop as long-term gains remain positive\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-11 21:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/institutional-investors-may-overlook-biocryst-pharmaceutical-1><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Insights  Institutions' substantial holdings in BioCryst Pharmaceuticals implies that they have significant influence over the company's share price   A total of 12 investors have a majority stake...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/institutional-investors-may-overlook-biocryst-pharmaceutical-1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210149790.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD-H","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/institutional-investors-may-overlook-biocryst-pharmaceutical-1","article_id":"2474018585","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2474018585","pubTimestamp":1728653327,"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Key Insights Institutions' substantial holdings in BioCryst Pharmaceuticals implies that they have significant...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4585":"ETF&股票定投概念",".IXIC":"NASDAQ Composite","BK4139":"生物科技","BCRX":"BioCryst制药","NDAQ":"纳斯达克OMX交易所","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","QID":"纳指两倍做空ETF","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4588":"碎股","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SQQQ":"纳指三倍做空ETF","BK4547":"WSB热门概念","QLD":"纳指两倍做多ETF","TQQQ":"纳指三倍做多ETF","BK4112":"金融交易所和数据","PSQ":"纳指反向ETF"},"translate_title":"机构投资者可能会忽视BioCryst Pharmaceuticals，Inc.（纳斯达克股票代码：BCRX）最近6200万美元的市值下跌，因为长期收益仍然为正","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCRX":1,".IXIC":1,"NDAQ":1,"TQQQ":0.6,"SQQQ":0.6,"QLD":0.6,"QID":0.6,"PSQ":0.6,"NQmain":0.6,"MNQmain":0.6},"content_text":"Key Insights  Institutions' substantial holdings in BioCryst Pharmaceuticals implies that they have significant influence over the company's share price   A total of 12 investors have a majority stake in the company with 51% ownership   Using data from analyst forecasts alongside ownership research, one can better assess the future performance of a company   Every investor in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) should be aware of the most powerful shareholder groups.  With 80% stake, institutions possess the maximum shares in the company.   In other words, the group stands to gain the most (or lose the most) from their investment into the company.  Institutional investors was the group most impacted after the company's market cap fell to US$1.5b last week.  However, the 19% one-year return to shareholders may have helped lessen their pain.  They should, however, be mindful of further losses in the future.     In the chart below, we zoom in on the different ownership groups of BioCryst Pharmaceuticals.  Check out our latest analysis for BioCryst Pharmaceuticals NasdaqGS:BCRX Ownership Breakdown October 11th 2024 What Does The Institutional Ownership Tell Us About BioCryst Pharmaceuticals? Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.   BioCryst Pharmaceuticals already has institutions on the share registry. Indeed, they own a respectable stake in the company.  This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong.  If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at BioCryst Pharmaceuticals' earnings history below. Of course, the future is what really matters. NasdaqGS:BCRX Earnings and Revenue Growth October 11th 2024  Investors should note that institutions actually own more than half the company, so they can collectively wield significant power.    It would appear that 6.1% of BioCryst Pharmaceuticals shares are controlled by hedge funds.  That catches my attention because hedge funds sometimes try to influence management, or bring about changes that will create near term value for shareholders.      Our data shows that BlackRock, Inc. is the largest shareholder with 10% of shares outstanding.       Meanwhile, the second and third largest shareholders, hold 9.1% and 6.1%, of the shares outstanding, respectively.     A closer look at our ownership figures suggests that the top 12 shareholders have a combined ownership of 51% implying that no single shareholder has a majority.    While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing.   Quite a few analysts cover the stock, so you could look into forecast growth quite easily.  Insider Ownership Of BioCryst Pharmaceuticals While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders.  Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.  I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.   Our data suggests that insiders own under 1% of BioCryst Pharmaceuticals, Inc. in their own names.   It's a big company, so even a small proportional interest can create alignment between the board and shareholders. In this case insiders own US$14m worth of shares.  Arguably, recent buying and selling is just as important to consider. You can  click here to see if insiders have been buying or selling.   General Public Ownership The general public, who are usually individual investors, hold a 13% stake in BioCryst Pharmaceuticals.   While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.   Next Steps: While it is well worth considering the different groups that own a company, there are other factors that are even more important.    Consider for instance, the ever-present spectre of investment risk.   We've identified 2 warning signs  with BioCryst Pharmaceuticals (at least 1 which is potentially serious)  , and understanding them should be part of your investment process.     If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.  NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.Valuation is complex, but we're here to simplify it.Discover if BioCryst Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2474018585"}